Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Ineligible for Transplant: Updated Analysis of Maia

Nizar J Bahlis; Thierry Facon; Saad Z Usmani; Shaji K. Kumar; Torben Plesner; Robert Z Orlowski; Cyrille Touzeau; Supratik Basu; Hareth Nahi; Cyrille Hulin; Hang Quach; Hartmut  Goldschmidt; Michael E. O'Dwyer; Christopher P. Venner; Katja Weisel; Maria Krevvata; Huiling Pei; Jianping Wang; Rian Van Rampelbergh; Jon Ukropec; Clarissa M Uhlar; Rachel Kobos; Aurore Perrot

doi:10.1182/blood-2019-123426

Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Ineligible for Transplant: Updated Analysis of Maia

Nizar J Bahlis, Thierry Facon, Saad Z Usmani, Shaji K. Kumar, Torben Plesner, Robert Z Orlowski, Cyrille Touzeau, Supratik Basu, Hareth Nahi, Cyrille Hulin, Hang Quach, Hartmut Goldschmidt, Michael E. O'Dwyer, Christopher P. Venner, Katja Weisel, Maria Krevvata, Huiling Pei, Jianping Wang, Rian Van Rampelbergh, Jon UkropecClarissa M Uhlar, Rachel Kobos, Aurore Perrot

IRS - Sygehus Lillebælt, Forskningsenhed for Hæmatologi (Vejle)

Publikation: Bidrag til tidsskrift › Konferenceabstrakt i tidsskrift › Forskning › peer review

Originalsprog	Engelsk
Artikelnummer	1875
Tidsskrift	Blood
Vol/bind	134
Udgave nummer	Suppl. 1
ISSN	0006-4971
DOI	https://doi.org/10.1182/blood-2019-123426
Status	Udgivet - nov. 2019
Begivenhed	American Society of Hematology: 61st Annual Meeting (ASH) - Orlando, USA Varighed: 7. dec. 2019 → 10. dec. 2019

Konference

Konference	American Society of Hematology: 61st Annual Meeting (ASH)
Land/Område	USA
By	Orlando
Periode	07/12/2019 → 10/12/2019

Dokumenter og links

10.1182/blood-2019-123426

Citationsformater

Bahlis, N. J., Facon, T., Usmani, S. Z., Kumar, S. K., Plesner, T., Orlowski, R. Z., Touzeau, C., Basu, S., Nahi, H., Hulin, C., Quach, H., Goldschmidt, H., O'Dwyer, M. E., Venner, C. P., Weisel, K., Krevvata, M., Pei, H., Wang, J., Van Rampelbergh, R., ... Perrot, A. (2019). Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Ineligible for Transplant: Updated Analysis of Maia. Blood, 134(Suppl. 1), Artikel 1875. https://doi.org/10.1182/blood-2019-123426

@article{6d043dc9374946109daccf63607e0577,

title = "Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Ineligible for Transplant: Updated Analysis of Maia",

author = "Bahlis, {Nizar J} and Thierry Facon and Usmani, {Saad Z} and Kumar, {Shaji K.} and Torben Plesner and Orlowski, {Robert Z} and Cyrille Touzeau and Supratik Basu and Hareth Nahi and Cyrille Hulin and Hang Quach and Hartmut Goldschmidt and O'Dwyer, {Michael E.} and Venner, {Christopher P.} and Katja Weisel and Maria Krevvata and Huiling Pei and Jianping Wang and {Van Rampelbergh}, Rian and Jon Ukropec and Uhlar, {Clarissa M} and Rachel Kobos and Aurore Perrot",

year = "2019",

month = nov,

doi = "10.1182/blood-2019-123426",

language = "English",

volume = "134",

journal = "Blood",

issn = "0006-4971",

publisher = "American Society of Hematology",

number = "Suppl. 1",

note = "American Society of Hematology: 61st Annual Meeting (ASH) ; Conference date: 07-12-2019 Through 10-12-2019",

}

Bahlis, NJ, Facon, T, Usmani, SZ, Kumar, SK, Plesner, T, Orlowski, RZ, Touzeau, C, Basu, S, Nahi, H, Hulin, C, Quach, H, Goldschmidt, H, O'Dwyer, ME, Venner, CP, Weisel, K, Krevvata, M, Pei, H, Wang, J, Van Rampelbergh, R, Ukropec, J, Uhlar, CM, Kobos, R & Perrot, A 2019, 'Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Ineligible for Transplant: Updated Analysis of Maia', Blood, bind 134, nr. Suppl. 1, 1875. https://doi.org/10.1182/blood-2019-123426

Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Ineligible for Transplant: Updated Analysis of Maia. / Bahlis, Nizar J; Facon, Thierry; Usmani, Saad Z et al.
I: Blood, Bind 134, Nr. Suppl. 1, 1875, 11.2019.

Publikation: Bidrag til tidsskrift › Konferenceabstrakt i tidsskrift › Forskning › peer review

TY - ABST

T1 - Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Ineligible for Transplant

T2 - American Society of Hematology: 61st Annual Meeting (ASH)

AU - Bahlis, Nizar J

AU - Facon, Thierry

AU - Usmani, Saad Z

AU - Kumar, Shaji K.

AU - Plesner, Torben

AU - Orlowski, Robert Z

AU - Touzeau, Cyrille

AU - Basu, Supratik

AU - Nahi, Hareth

AU - Hulin, Cyrille

AU - Quach, Hang

AU - Goldschmidt, Hartmut

AU - O'Dwyer, Michael E.

AU - Venner, Christopher P.

AU - Weisel, Katja

AU - Krevvata, Maria

AU - Pei, Huiling

AU - Wang, Jianping

AU - Van Rampelbergh, Rian

AU - Ukropec, Jon

AU - Uhlar, Clarissa M

AU - Kobos, Rachel

AU - Perrot, Aurore

PY - 2019/11

Y1 - 2019/11

U2 - 10.1182/blood-2019-123426

DO - 10.1182/blood-2019-123426

M3 - Conference abstract in journal

SN - 0006-4971

VL - 134

JO - Blood

JF - Blood

IS - Suppl. 1

M1 - 1875

Y2 - 7 December 2019 through 10 December 2019

ER -